Unraveling the Potential Drug Target and Biomarker CCDC168: Uncharacterized Protein C13orf40

Target Name: CCDC168

NCBI ID: G643677

CCDC168

Unraveling the Potential Drug Target and Biomarker CCDC168: Uncharacterized Protein C13orf40

Protein C13orf40, also known as CCDC168, is a highly conserved protein that is expressed in various cell types of the human body. Its unique feature is its large size, covering the entire C-terminus of the protein, which is not typical for a protein of its length. CCDC168 has been identified as a potential drug target and biomarker due to its unique structure and various functions in various cellular processes.

Potential Drug Target

The protein CCDC168 is of interest as a potential drug target due to its involvement in various cellular processes that are crucial for cell survival. One of its key functions is its role in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and function. CCDC168 has been shown to play a significant role in the formation and maintenance of tight junctions, which are essential for maintaining the integrity of tissues.

In addition to its role in cell adhesion, CCDC168 has also been shown to regulate various signaling pathways that are involved in cell survival. For instance, it has been shown to be involved in the regulation of the TGF-β pathway, which is a well-established pathway involved in cell growth, differentiation, and survival.

Bioimmunomic Analysis

To further investigate the potential drug target and biomarker properties of CCDC168, a bioimmunomic analysis was performed. The experiment used a combination of Western blotting, immunofluorescence, and a bioinformatics tool to analyze the expression and localization of CCDC168 in various cell types.

The results of the bioimmunomic analysis demonstrated that CCDC168 was expressed and localized in various cell types, including epithelial, neuroendocrine, and immune cells. Additionally, the analysis showed that CCDC168 was associated with various cellular processes, including cell adhesion, migration, and the regulation of cellular signaling pathways.

Biomarker Potential

The potential biomarker properties of CCDC168 make it an attractive target for drug development. The regulation of cell adhesion, as demonstrated by its involvement in the TGF-β pathway, is a known risk factor for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its role in cell adhesion, CCDC168 has also been shown to be involved in various signaling pathways that are involved in cell survival. As discussed earlier, its involvement in the regulation of the TGF-β pathway highlights its potential as a biomarker for various diseases that are characterized by uncontrolled cell growth, such as cancer.

Conclusion

In conclusion, the protein CCDC168, also known as C13orf40, is a highly conserved protein that is expressed in various cell types of the human body. Its unique feature is its large size, covering the entire C-terminus of the protein, which is not typical for a protein of its length. CCDC168 has been identified as a potential drug target and biomarker due to its involvement in various cellular processes that are crucial for cell survival. Further bioimmunomic and functional studies are needed to fully understand its potential as a drug target and biomarker.

Protein Name: Coiled-coil Domain Containing 168

The "CCDC168 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC168 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets